Literature DB >> 22797491

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges.

D Bauer1, J Krege, N Lane, E Leary, C Libanati, P Miller, G Myers, S Silverman, H W Vesper, D Lee, M Payette, S Randall.   

Abstract

UNLABELLED: This position paper reviews how the National Bone Health Alliance (NBHA) will execute a project to help assure health professionals of the clinical utility of bone turnover markers; the current clinical approaches concerning osteoporosis and the status and use of bone turnover markers in the USA; the rationale for focusing this effort around two specific bone turnover markers; the need to standardize bone marker sample collection procedures, reference ranges, and bone turnover marker assays in clinical laboratories; and the importance of harmonization for future research of bone turnover markers.
INTRODUCTION: Osteoporosis is a major global health problem, with the prevalence and incidence of osteoporosis for at-risk populations estimated to be 44 million Americans. The potential of bone markers as an additional tool for health care professionals to improve patient outcomes and impact morbidity and mortality is crucial in providing better health care and addressing rising health care costs. This need to advance the field of bone turnover markers has been recognized by a number of organizations, including the International Osteoporosis Foundation (IOF), National Osteoporosis Foundation, International Federation of Clinical Chemistry, and Laboratory Medicine (IFCC), and the NBHA.
METHODS: This position paper elucidates how this project will standardize bone turnover marker sample collection procedures in the USA, establish a USA reference range for one bone formation (serum procollagen type I N propeptide, s-PINP) and one bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) marker, and standardize bone turnover marker assays used in clinical laboratories. This effort will allow clinicians from the USA to have confidence in their use of bone turnover markers to help monitor osteoporosis treatment and assess future fracture risk. This project builds on the recommendations of the IOF/IFCC Bone Marker Standards Working Group by developing USA reference standards for s-PINP and s-CTX, the markers identified as most promising for use as reference markers.
RESULTS: The goals of this project will be realized through the NBHA and will include its governmental, academic, for-profit, and non-profit sector stakeholders as well as major academic and commercial laboratories. Upon completion, a parallel effort will be pursued to make bone turnover marker measurements reliable and accepted by all health care professionals for facilitating treatment decisions and ultimately be reimbursed by all health insurance payers.
CONCLUSIONS: Successful completion of this project will help assure health professionals from the USA of the clinical utility of bone turnover markers and ties in with the parallel effort of the IOF/IFCC to develop worldwide bone turnover reference ranges.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22797491      PMCID: PMC4011662          DOI: 10.1007/s00198-012-2049-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  43 in total

1.  Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.

Authors:  P Garnero; E Sornay-Rendu; B Claustrat; P D Delmas
Journal:  J Bone Miner Res       Date:  2000-08       Impact factor: 6.741

2.  Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy.

Authors:  H N Rosen; A C Moses; J Garber; I D Iloputaife; D S Ross; S L Lee; S L Greenspan
Journal:  Calcif Tissue Int       Date:  2000-02       Impact factor: 4.333

3.  PINP as an aid for monitoring patients treated with teriparatide.

Authors:  Mika Tsujimoto; Peiqi Chen; Akimitsu Miyauchi; Hideaki Sowa; John H Krege
Journal:  Bone       Date:  2010-12-17       Impact factor: 4.398

4.  Roadmap for harmonization of clinical laboratory measurement procedures.

Authors:  W Greg Miller; Gary L Myers; Mary Lou Gantzer; Stephen E Kahn; E Ralf Schönbrunner; Linda M Thienpont; David M Bunk; Robert H Christenson; John H Eckfeldt; Stanley F Lo; C Micha Nübling; Catharine M Sturgeon
Journal:  Clin Chem       Date:  2011-06-15       Impact factor: 8.327

5.  Biochemical markers as predictors of rates of bone loss after menopause.

Authors:  A Rogers; R A Hannon; R Eastell
Journal:  J Bone Miner Res       Date:  2000-07       Impact factor: 6.741

Review 6.  Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care.

Authors:  Randie R Little; Curt L Rohlfing; David B Sacks
Journal:  Clin Chem       Date:  2010-12-09       Impact factor: 8.327

7.  Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study.

Authors:  Douglas C Bauer; Patrick Garnero; Stephanie L Harrison; Jane A Cauley; Richard Eastell; Kris E Ensrud; Eric Orwoll
Journal:  J Bone Miner Res       Date:  2009-12       Impact factor: 6.741

Review 8.  Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.

Authors:  S Vasikaran; R Eastell; O Bruyère; A J Foldes; P Garnero; A Griesmacher; M McClung; H A Morris; S Silverman; T Trenti; D A Wahl; C Cooper; J A Kanis
Journal:  Osteoporos Int       Date:  2010-12-24       Impact factor: 4.507

9.  Laboratory reproducibility of biochemical markers of bone turnover in clinical practice.

Authors:  A L Schafer; E Vittinghoff; R Ramachandran; N Mahmoudi; D C Bauer
Journal:  Osteoporos Int       Date:  2009-06-09       Impact factor: 4.507

10.  Age-dependence of femoral strength in white women and men.

Authors:  Tony M Keaveny; David L Kopperdahl; L Joseph Melton; Paul F Hoffmann; Shreyasee Amin; B Lawrence Riggs; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2010-05       Impact factor: 6.741

View more
  42 in total

1.  Reference intervals of bone turnover markers determined by using their curve-fitting valley for adult females in China.

Authors:  X-Y Wu; H Zhang; H Xie; X-H Luo; Y-Q Peng; L-Q Yuan; R-C Dai; Z-F Sheng; X-P Wu; E-Y Liao
Journal:  Osteoporos Int       Date:  2013-07-23       Impact factor: 4.507

2.  The utility of procollagen type 1 N-terminal propeptide for the bone status assessment in postmenopausal women.

Authors:  Elma Kučukalić-Selimović; Amina Valjevac; Almira Hadžović-Džuvo
Journal:  Bosn J Basic Med Sci       Date:  2013-11       Impact factor: 3.363

Review 3.  Bone remodeling markers and bone metastases: From cancer research to clinical implications.

Authors:  Arlindo Ferreira; Irina Alho; Sandra Casimiro; Luís Costa
Journal:  Bonekey Rep       Date:  2015-04-22

4.  Histomorphometric diagnostics of renal osteopathy in chronic dialysis patients at high risk of cardiovascular disease.

Authors:  K Žamboch; K Krejčí; J Škarda; M Tichý; I Überall; P Skýpalová; K Langová; D Stejskal; M Švesták; J Zahálková; V Ščudla; J Zadražil
Journal:  Int Urol Nephrol       Date:  2015-05-01       Impact factor: 2.370

5.  The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis.

Authors:  Samuel D Vasikaran; S A Paul Chubb
Journal:  Endocrine       Date:  2016-02-23       Impact factor: 3.633

Review 6.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

7.  National Bone Health Alliance: an innovative public-private partnership improving America's bone health.

Authors:  David B Lee; Mia Rochelle Lowden; Valerie Patmintra; Katie Stevenson
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

Review 8.  [Biochemical markers of bone metabolism and their importance].

Authors:  B Obermayer-Pietsch; V Schwetz
Journal:  Z Rheumatol       Date:  2016-06       Impact factor: 1.372

Review 9.  Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.

Authors:  Laura Evangelista; Francesco Bertoldo; Francesco Boccardo; Giario Conti; Ilario Menchi; Francesco Mungai; Umberto Ricardi; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-09       Impact factor: 9.236

Review 10.  Chronic kidney disease and osteoporosis: evaluation and management.

Authors:  Paul D Miller
Journal:  Bonekey Rep       Date:  2014-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.